{"summary": "compounds of the 1,2,3-triazole family have shown a broad spectrum of biological activities, including antibacterial [1,2], antifungal [3,4,5,6], anticancer [7,8,9,10,11], antiviral [12,13,14,15,16] and antiallergic effects [17]. substituted 1,2,3-triazoles have also been used as agrochemicals, dyes, photostabilisers and corrosion inhibitors. naphthalimides containing triazole units proved their cytotoxic activity. cytotoxicity against MCF-7, HeLa and 7721 cells was evaluated. naphthalimides 4 derivatives were found the most active. compounds 14\u201317 resemble analogues of acyclic nucleotides in which the phosphate group is replaced with a phosphonate moiety and a naphthalimide fragment serves as a modified nucleobase. in principle compounds 14\u201317 may act as intercalators (through a naphthalimide ring) but also by a phosphonate activation and termination of DNA/RNA synthesis. chromatographic purification or crystallization gave pure 14a\u2013i\u201317a\u2013i in good to excellent yields. their structures and purities were established by 1H, 13C and 31P NMR and IR techniques as well as by elemental analyses. the antiviral activity was expressed as the EC50. the compound concentration required to reduce virus-induced cytopathogenicity by 50%. acyclovir and brivudine were used as reference drugs. 14c >100 64.47 >100 n.d. 14d 86.39 56.66 >100 n.d. 14e 69.93 >100 >100 n.d. 14h >100 74.63 >100 n.d. 15b 34.2 38.07 >100 n.d. 15f 86.39 >100 n.d. 15h 37.14 70.83 >100 n.d. 16b >100 27.59 100 n. a 50% decrease in cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay system. none of the tested compounds affected cell morphology of HEL, HeLa, Vero, MDCK and CRFK cells at concentrations up to 100 M. 250 >250 15a 28 1 60 27 88 5 185 40 15b 14 1 56 20 62 20 152 1 15c 20 3 52 34 62 1 152 0 15d 17 3 22 0 55 2 92 43 15e 42 15 196 60 >250 >250 15f 23 3 60 13 87 21 152 1 15g 24 3 66 20 84 16 152 1 15h 26 2 29 11 61 15 151 0 15i 31 2 137 72 >250 >250 16 n.d 17g >250 >250 97 42 n.d 17h 142 2 109 3 66 3 n.d 17i >250 >250 112 58 n.d Amonafide 1.0 0.4 0.54 0.50 2.0 1.2 0.31 0.00 a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%, n.d.\u2014not determined. the synthetic strategy to the 1,2,3-triazole-containing naphthalimide derivatives 14a\u2013i\u201317a\u2013i is presented in Scheme 1 and Scheme 2. the syntheses of alkynes 7 [37,38,39] and 8 [40,41,42] have been previously described. naphthalimides 14a\u2013i\u201317a\u2013i having various phosphonoalkyl groups regioselectively installed at N-1 of the 1,2,3-triazole subunit (Scheme 2). their structures and purities were established by 1H, 13C and 31P NMR and IR techniques. the antiviral activity was expressed as the EC50. the compound concentration required to reduce virus-induced cytopathogenicity by 50%. acyclovir and brivudine were used as reference compounds. 14d 86.39 56.66 >100 n.d. 14e 69.93 >100 >100 n.d. 14h >100 74.63 >100 n.d. 15b 34.2 38.07 >100 n.d. 15f 86.44 37.54 100 n.d. 15h 37.14 70.83 >100 n.d. 16b >100 27.59 100 n.d. 16c 32.82 47.82 >100 the 50% cytotoxic concentration (CC50) causing a 50% decrease in cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay system. 250 14h 196 32 171 25 154 22 222 39 14i >250 250 >250 15a 28 1 60 27 88 5 185 40 15b 14 1 56 20 62 20 152 1 15c 20 3 52 34 62 1 152 0 15d 17 3 22 0 55 2 92 43 15e 42 15 196 60 >250 >250 15f 23 3 60 13 87 21 152 1 15g 24 3 66 20 84 16 152 1 15h 26 2 29 11 n.d. 17e >250 >250 72 58 n.d 17h 142 2 109 3 66 3 n.d 17i >250 >250 112 58 n.d Amonafide 1.0 0.4 0.54 0.50 2.0 1.2 0.31 0.00 a 50% Inhibitory concentration or compound concentration required to inhibit tumor cell proliferation by 50%, n.d.\u2014not determined. naphthalimides 14a\u2013i could be considered inactive (IC50 = 48 M) naphthalimides 14a\u2013i could be considered inactive (IC50 = 150\u2013>250 M) adsorbents were used: column chromatography, silica gel 60 (70\u2013230 mesh, Merck KGaA, Darmstadt, Germany); analytical TLC, Merck TLC plastic sheets silica gel 60 F254. all solvents were purified by methods described in the literature. d, J = 2.5 Hz, 1H, HCCCH2), 2.20 (t, J = 2.5 Hz, 2H, HCCCH2). reaction mixture was stirred at 78 \u00b0C for 4 h. reaction mixture was cooled to room temperature then filtered to give 11 as an orange powder. a suspension of compound 10 (1.00 mmol) in ethanol (15 mL) was stirred at 78 \u00b0C for 3 h. the reaction mixture was cooled to room temperature and filtered to give 12 as orange needles which were pure. a solution of azidoalkylphosphonate 13a\u2013i (1.00 mmol) in EtOH (1.0 mL) and H2O (1.0 mL), CuSO4 5H2O (0.10 mmol), sodium ascorbate (0.20 mmol) and the respective N-propargyl naphthalimides 7/8\u201311/12 (1.00 mmol) were added. the reaction mixture was microwave irradiated at 35\u201340 zol-1-ylmethylphosphonate: Yield 81% (after crystallization from an ethyl acetate\u2013hexane mixture) zol-1-ylmethylphosphonate: Yield 81% (after crystallization from an ethyl acetate\u2013hexane mixture) diethyl 2-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethylphosphonate (14b): Yield 79% (after crystallization from an ethyl acetate\u2013hexane mixture) ethyl 3-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylpropylphosphonate (14c): Yield 78% (after crystallization from an ethyl acetate\u2013hexane mixture). qu, J = 21.7 Hz, J = 6.9 Hz, 2H, PCH2CH2), 1.72 (dt, J = 18.6 Hz, J = 8.0 Hz, 2H, PCH2), 1.30 (t, J = 7.1 Hz, 6H, 2 POCH2CH3); 13C-NMR (151 MHz, CDCl3): = 163.84, 143.52, 134.12, 131.64, 131.48, 128 1H-NMR (200 MHz, CDCl3): = 8.61 (dd, J = 7.3 Hz, J = 1.0 Hz, 2H, Haromat.), 7.74 (d, J = 8.3 Hz, J = 1.0 Hz, 2H, Haromat.), 7.63 (s, 1H, HC5\u2032), 5.50 (s, 2H, CH2), 4.30 (t, J = 7.2 Hz, 2H, PCCCCH diethyl 2-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-yl-1-hydroxyethylphosphonate (14e): Yield 80% (after crystallization from a methanol\u2013diethyl ether mixture) t, J = 7.0 Hz, 3H, POCH2CH3), 1.32 (t, J = 7.0 Hz, 3H, POCH2CH3); 13C-NMR (151 MHz, CDCl3): = 163.74, 143.38, 134.04, 131.50, 131.35, 128.07, 126.87, 124.98, 122.2, 67.19 (d, J = 164.6 Hz, PC), 8.20 (dd, J = 8.3 Hz, J = 0.9 Hz, 2H, Haromat.), 7.82 (s, 1H, HC5\u2032), 7.73 (dd, J = 7.9 Hz, J = 8.3 Hz, 2H, Haromat.), 5.51 (s, 2H, CH2), 4.55\u20134.27 (m, 3H, PCCCH2, OH), 4.19\u20133.96 (m, 5H, PCCH, 2 H-1,2,3-triazol-1-ylethoxy-methylphosphonate (14g): Yield 82% (after crystallization from a methanol\u2013diethyl ether mixture) diethyl 2-(2-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy)ethylphosphonate (14h): Yield 79%. POCH2CH3), 3.77 (t, J = 5.3 Hz, 2H, PCCOCH2CH2), 3.64 (dt, J = 11.8 Hz, J = 7.6 Hz, 2H, PCH2CH2O), 2.03 (dt, J = 18.7 Hz, 6H, 2 POCH2CH3); 13C-NMR (151 MHz, CDCl3): = 163.86, 143.56, 134.07, 131.63, 1H-NMR (200 MHz, CDCl3): = 8.51 (dd, J = 7.3 Hz, J = 1.1 Hz, 2H, Haromat.), 8.12 (dd, J = 8.2 Hz, J = 1.1 Hz, 2H, Haromat.), 7.80 (s, 1H, HC5\u2032), 7.66 (dd, J = 5.9 Hz, 1H, NHCO), 5.44 (s, 2H, diethyl 4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylmethylphosphonate (15a) Yield 82% (after column chromatography with chloroform\u2013methanol mixtures) diethyl 2-4-(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl)-1H-1,2,3-triazol-1-ylethylphosphonate: Yield 80% (after crystallization from ethyl acetate). 7.64 (s, 1H, HC5\u2032), 5.48 (s, 2H, CH2), 4.07\u20133.93 (m, 4H, 2 POCH2CH3), 2.41\u20132.29 (m, 2H, PCH2), 1.21 (t, J = 7.1 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, CDCl3): = 163.15, 163.14, 143.43, 133.42, 132 2990, 2942, 2829, 1705, 1666, 1590, 1234, 1047, 1029, 752 cm1; 1H-NMR (151 MHz, CDCl3): = 8.68 (dd, J = 7.3 Hz, J = 1.2 Hz, 1H, Haromat.), 8.04 (d, J = 7.9 Hz, 1H, Haromat.), 7.84 (dd, J = 8.3 Hz, J = 7.2 diethyl 4-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylbutylphosphonate: Yield 88% (after crystallization from an ethyl acetate\u2013hexane mixture). Hz, 2H, PCCCCH2), 4.12\u20133.97 (m, 4H, 2 POCH2CH3), 1.84\u20131.49 (m, 2H, PCCCH2), 1.30 (t, J = 7.2 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, CDCl3): = 163.25, 163.22, 143.41, 133.43, 131.09, 130.65, 130.50, 130 1H-NMR (200 MHz, CDCl3): = 8.50 (dd, J = 7.3 Hz, J = 1.1 Hz, 1H, Haromat.), 8.44 (d, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 8.26 (d, J = 7.9 Hz, 1H, Haromat.), 7.94 (d, J = 7.9 Hz, 1H, Haromat.), 7.88 125.10, 122.73, 121.87, 67.20 (d, J = 164.6 Hz, PC), 63.40 (d, J = 7.6 Hz, POC), 51.64 (d, J = 9.1 Hz, PCC), 35.27, 16.44 (d, J = 6.0 Hz, POCC), 16.40 (d, J = 6.0 Hz, POCC), 31P-NMR (81 MHz, CDCl3): J = 7.9 Hz, 1H, Haromat.), 7.90 (s, 1H, HC5\u2032), 7.65 (dd, J = 8.5 Hz, J = 7.5 Hz, 1H, Haromat.), 5.49 (s, 2H, CH2), 4.52\u20134.17 (m, 3H, PCCCH2, OH), 2.10\u20131.60 (m, 2H, PCH2), 1.33 and 1.29 (t, J = 7.0 -2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy-methylphosphonate (15g): Yield 90% (after crystallization from an ethyl acetate\u2013hexane mixture) ethyl 2-(2-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy)ethylphosphonate (15h): Yield 86% (after crystallization from an ethyl acetate\u2013hexane mixture). 8.10 (d, J = 7.9 Hz, 1H, Haromat.), 7.84 (dd, J = 8.3 Hz, J = 7.3 Hz, 1H, Haromat.), 7.76 (s, 1H, HC5\u2032), 5.52 (s, 2H, CH2), 4.49 (t, J = 5.3 Hz, 2H, PCH2CH2OCH2CH2), 4.18\u20133.95 (m, 4H, 2 POCH2 diethyl 2-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylacetamido-methylphosphonate (15i) Yield 88% (after column chromatography with chloroform\u2013methanol mixtures (100:1 or 50:1, v/v) d, J = 5.5 Hz, C=O), 163.25, 163.24, 143.76, 133.49, 132.29, 131.45, 131.12, 130.62, 130.54, 128.99, 128.07, 125.02, 122.85, 121.98, 62.87 (d, J = 6.6 Hz, POC), 52.57, 35.25, 35.00 (d, J = 5.4 Hz, 8.36 (dd, J = 8.4 Hz, J = 1.2 Hz, 1H, Haromat.), 7.88 (dd, J = 8.4 Hz, J = 7.4 Hz, 1H, Haromat.), 7.84 (s, 1H, HC5\u2032), 5.47 (s, 2H, CH2), 4.66 (d, J = 13.1 Hz, 2H, PCH2), 4.13\u20133.98 (m, 4H, 2 POCH ethyl acetate\u2013hexane mixture crystallized 88%. dd, J = 2.2 Hz, 1H, Haromat. 8.38 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat. diethyl 3-4-[(5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylpropylphosphonate: Yield 80% (after crystallization from ethyl acetate). m, 4H, 2 POCH2CH3), 2.30\u20132.08 (m, 2H, PCH2), 1.29 (t, J = 7.0 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, CDCl3): = 162.76, 162.25, 146.37, 143.06, 135.77, 135.77, 135.77, 135.74, 130.26, 129.11, 124.56, 124. 1H-NMR (200 MHz, CDCl3): = 9.31 (d, J = 2.1 Hz, 1H, Haromat.), 9.13 (d, J = 2.1 Hz, 1H, Haromat.), 8.79 (dd, J = 7.4 Hz, J = 1.1 Hz, 1H, Haromat.), 8.42 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 7. diethyl 2-4-[(5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-yl-1-hydroxyethylphosphonate (16e): Yield 83% (after crystallization from an ethyl acetate\u2013hexane mixture). Hz, J = 6.8 Hz, J = 2.6 Hz, 1H, PCCHaHb, PCH, 4.52\u20134.27 (m, 2H, PCCHaHb, PCH), 4.26\u20134.08 (m, 4H, 2 POCH2CH3), 1.34 (t, J = 7.0 Hz, 3H, POCH2CH3), 1.32 (t, J = 7.0 Hz, 3H, POCH2CH3); 13C-N 1H-NMR (200 MHz, CDCl3): = 9.31 (d, J = 2.2 Hz, 1H, Haromat.), 9.13 (d, J = 2.2 Hz, 1H, Haromat.), 8.79 (dd, J = 7.4 Hz, J = 1.2 Hz, 1H, Haromat.), 7.94 (dd, J = 8.2 Hz, J = 1.2 Hz, 1H, Haromat.), 7. d, J = 6.4 Hz, POC), 55.75 (d, J = 16.6 Hz, PCCC), 35.55, 30.56 (d, J = 6.0 Hz, PCCC), 16.32 (d, J = 6.0 Hz, POCC), 31P-NMR (81 MHz, CDCl3): 29.28 ppm. 7.82 (s, 1H, HC5\u2032), 5.51 (s, 2H, CH2), 4.52 (t, J = 4.8 Hz, 2H, PCH2OCH2CH2), 4.18\u20134.04 (m, 4H, 2 POCH2CH3) 3.95 (d, J = 8.2 Hz, 2H, PCH2CH2), 3.75 (d, J = 7.1 Hz, 6H, 2 POCH2CH3); 13C-NMR column chromatography with chloroform\u2013methanol mixtures (100:1 or 50:1, v/v); 1H-NMR (200 MHz, CDCl3): = 9.30 (d, J = 2.2 Hz, 1H, Haromat.), 9.12 (d, J = 2.2 Hz, 1H, Haromat.), 8.78 (dd, J = 7.3 Hz, J = 1.2 Hz, 1H, Haromat.), 7.93 ( .03, 124.65, 124.40, 124.37, 123.17, 68.96, 65.25 (PCCO), 61.68 (d, J = 6.0 Hz, POC), 50.13, 35.57, 26.87 (d, J = 140.4 Hz, PC), 16.41 (d, J = 6.1 Hz, POCC); 31P-NMR (81 MHz, CDCl3): = 28.70 ppm d, J = 8.2 Hz, J = 7.5 Hz, 1H, Haromat.), 8.03 (s, 1H, HC5\u2032), 5.36 (s, 2H, CH2), 5.10 (s, 2H), 4.19\u20133.97 (m, 4H, 2 POCH2CH3). 1H-NMR (600 MHz, DMSO-d6): 8.10 (d, J = 7.2 Hz, 1H, Haromat.), 8.07 (d, J = 8.2 Hz, 1H, Haromat.), 8.95 (d, s, 1H, HC5\u2032), 7.64 (d, J = 8.2 Hz, J = 7.2 Hz, 1H, Haromat.), 6.01 (s, 2H, NH2), 5. diethyl 2-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethylphosphonate (17b): Yield 75% after column chromatography with chloroform\u2013methanol mixtures (100:1 and 50:1, v/v) 2H, PCH2), 1.26 (t, J = 7.2 Hz, 6H, 2 POCH2CH3); 13C-NMR (151 MHz, CDCl3): = 8.28. dd, J = 7.3 Hz, J = 0.8 Hz, 1H, Haromat. 7.87 (dd, J = 8.2 Hz, J = 0.8 Hz, 1H, Haromat.), 7.70 (s, 1H, HC5\u2032), 7.56 (d, J = 2.3 Hz, 1H, Haromat.), 5.49 (s, 2H, CH2), 4.42 (t, J = 6.9 Hz, 2H, diethyl 4-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylbutylphosphonate (17d): Yield 70% (after column chromatography with chloroform\u2013methanol mixtures (100:1 and 50:1, v/v) 4.20\u20134.00 (m, 4H, 2 POCH2CH3), 1.80\u20131.60 (m, 4H, PCCH2 and PCH2), 1.30 (t, J = 7.0 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, DMSO-d6): = 163.99, 163.81, 148.39, 143.61, 134.08, 132.15, 127.42, 126.04 1H-NMR (600 MHz, DMSO-d6): 8.10 (d, J = 7.3 Hz, 1H, Haromat.), 8.05 (d, J = 8.2 Hz, 1H, Haromat.), 8.05 (d, J = 8.2 Hz, J = 7.3 Hz, 1H, Haromat.), 7.63 (d, J = 2.3 Hz, 1H, Haromat.), 7.30 (d, J = 2.3 63.36 (d, J = 6.8 Hz, POC), 52.46 (d, J = 11.7 Hz, PCC), 34.41, 16.60 (d, J = 4.7 Hz, 2 POCC); 31P-NMR (243 MHz, DMSO-d6): = 25.85 ppm. 7.31 (brs, 2H, NH2), 5.35 (brs, 1H, OH), 5.29 (s, 2H, CH2), 4.45 (dd, J = 13.8 Hz, J = 3.6 Hz, 1H, PCCCHaHb), 4.26 (dd, J = 13.8 Hz, J = 7.7 Hz, 1H, PCCCHaHb), 4.15\u20134.09 (m, 1H, PCCH), 4. diethyl 2-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy-methylphosphonate (17g): Yield 77% (after column chromatography with chloroform\u2013methanol mixtures (100:1 or 50:1, v/v) m, 6H, 2 POCH2CH3, PCOCH2CH2), 3.92\u20133.88 (d, J = 8.3 Hz, 2H, PCH2CH3), 1.12 (t, J = 7.1 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, DMSO-d6): = 164.04, 163.80, 148.40, 143.56, 134.09, 132.17, 127.44, 1H-NMR (600 MHz, CDCl3): 8.33 (d, J = 7.2 Hz, 1H, Haromat.), 8.06 (d, J = 2.2 Hz, 1H, Haromat.), 7.82 (d, J = 8.2 Hz, 1H, Haromat.), 7.78 (s, 1H, HC5\u2032), 7.54 (d, J = 8.2 Hz, J = 7.2 Hz, 1H, Haromat d, J = 6.4 Hz, POC), 49.71, 35.68, 26.28 (d, J = 137.2 Hz, PC), 16.64 (d, J = 5.6 Hz, PC), 31P-NMR (243 MHz, CDCl3): 27.84 ppm. herpes simplex virus type 1 strain KOS, thymidine kinase-deficient (TK) strain resistant to ACV (ACVr), herpes simplex virus type 2 strains Lyons and G, varicella-zoster virus (VZV) strain Oka. TK VZV strain 071, human cytomegalovirus (HCMV) strains AD-169 and Davis, vaccinia virus Lederle strain, long, vesicular stomatitis virus (VSV), Coxsackie B4, Parainfluenza 3, Influenza virus A (subtypes H1N1, H3N2), influenza virus B, Reovirus-1, Sindbis, Reovirus-1, Punta Toro, human immunodeficiency virus the IC50 (50% inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50%. 13C-NMR spectra were recorded on a Bruker Avance III (600 MHz) spectrometer at 151 MHz. all solvents were purified by methods described in the literature. all microwave irradiation experiments were carried out in a RM 800 microwave reactor. ione (11) A suspension of compound 9 (1.00 mmol) in ethanol (15 mL) was stirred at 78 \u00b0C for 4 h. the reaction mixture was cooled to room temperature then filtered to give 11 as an orange powder which was pure to be used in next step without further purification. a suspension of compound 10 (1.00 mmol) in ethanol (15 mL) was stirred at 78 \u00b0C for 3 h. the reaction mixture was cooled to room temperature and filtered to give 12 as orange needles which were pure to be used in next step without further purification. a solution of azidoalkylphosphonate 13a\u2013i (1.00 mmol) in EtOH (1.0 mL) and H2O (1.0 mL), CuSO4 5H2O (0.10 mmol), sodium ascorbate (0.20 mmol) and the respective N-propargyl naphthalimides 7/8\u201311/12 (1.00 mmol) were added. the reaction mixture was microwave irradiated at 35\u201340 1H-NMR (200 MHz, CDCl3): = 8.54 (dd, J = 7.3 Hz, J = 1.2 Hz, 2H, Haromat.) 7.86 (s, 1H, HC5\u2032), 7.70 (dd, J = 8.1 Hz, J = 1.2 Hz, 2H, Haromat.) 1H-NMR (200 MHz, CDCl3): = 8.62 (dd, J = 7.3 Hz, J = 1.2 Hz, 2H, Haromat.), 8.75 (dd, J = 8.3 Hz, J = 1.2 Hz, 2H, Haromat.), 7.69 (s, 1H, HC5\u2032), 5.51 (s, 2H, CH2), 4.62\u20134.48 (m, 2H, PCH2CH2), diethyl 3-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylpropylphosphonate: Yield 78% (after crystallization from an ethyl acetate\u2013hexane mixture) 128.25, 126.92, 123.40, 122.55, 61.74 (d, J = 6.5 Hz, POC), 50.02 (d, J = 15.5 Hz, PCCC), 35.25, 23.65 (d, J = 4.5 Hz, PCC), 22.66 (d, J = 6.2 Hz, PCC), 16.39 (d, J = 6.2 Hz, POCC), 31P-NMR (243 MHz Hz, J = 7.3 Hz, 2H, Haromat.), 7.63 (s, 1H, HC5\u2032), 5.50 (s, 2H, CH2), 4.30 (t, J = 7.2 Hz, 2H, PCCCCH2), 4.13\u20133.95 (m, 4H, 2 POCH2CH3), 2.80\u20131.49 (m, 4H, PCCH2 and PCH2), 1.80\u20131.49 (m, 4H, PCCH2 methanol\u2013diethyl ether mixture crystallized from a methanol\u2013diethyl ether mixture. methanol\u2013diethyl ether mixture is a white solid; m.p. 186\u2013188 \u00b0C; IR. 67.19 (d, J = 164.6 Hz, PC), 63.58 and 63.24 (2 d, J = 7.6 Hz, 2 POC), 51.57 (d, J = 9.1 Hz, PCC), 35.20, 16.42 and 16.38 (2 d, J = 6.0 Hz, 2 POCC); 31P-NMR (243 MHz, CDCl3): = 19.89 ppm. 3H, PCCCH2, OH), 4.19\u20133.96 (m, 5H, PCCH, 2 POCH2CH3), 2.06\u20131.67 (m, 2H, PCH2), 1.32 and 1.26 (t, J = 7.0 Hz, 3H, POCH2CH3), 13C-NMR (151 MHz, CDCl3). 1H-NMR (200 MHz, CDCl3): = 8.60 (dd, J = 7.3 Hz, J = 1.0 Hz, 2H, Haromat.), 8.19 (dd, J = 8.3 Hz, J = 1.0 Hz, 2H, Haromat.), 7.77 (s, 1H, HC5\u2032), 7.74 (dd, J = 8.3 Hz, J = 1.0 Hz, 2H, Haromat.), diethyl 2-(2-4-[(1,3-Dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy)ethylphosphonate (14h): Yield 79% (after crystallization from a methanol\u2013diethyl ether mixture) 13C-NMR (151 MHz, CDCl3): = 163.86, 143.56, 134.07, 131.63, 131.44, 128.25, 126.92, 124.28, 122.60, 68.90, 65.23 (PCCO), 50.06, 35.27, 26.33 (d, J = 6.1 Hz, POCC) Hz, 2H, Haromat.), 7.80 (s, 1H, HC5\u2032), 7.66 (dd, J = 8.2 Hz, J = 7.3 Hz, 2H, Haromat.), 7.49 (dd, J = 5.9 Hz, 1H, NHCO), 5.44 (s, 2H, CH2), 5.01 (s, 2H), 4.06\u20133.92 (m, 4H, 2 POCH2CH3), 3.62 (d 1H-NMR (600 MHz, CDCl3): = 8.67 (d, J = 7.8 Hz, 1H, Haromat.), 8.59 (d, J = 7.8 Hz, 1H, Haromat.), 8.05 (d, J = 7.8 Hz, 1H, Haromat.), 7.88 (s, 1H, HC5\u2032), 7.86 (dd, J = 8.5 Hz, J = 7.8 Hz, 1H, Har diethyl 2-4-(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl)-1H-1,2,3-triazol-1-ylethylphosphonate: Yield 80% (after crystallization from ethyl acetate) 13C-NMR (151 MHz, CDCl3): = 163.15, 163.14, 143.43, 133.42, 132.22, 131.38, 131.09, 130.58, 130.48, 128.94, 128.06, 123.58, 122.85, 121.98, 62.09. 8.04 (d, J = 7.9 Hz, 1H, Haromat.), 8.04 (d, J = 7.9 Hz, 1H, Haromat.), 7.84 (d, J = 8.3 Hz, J = 7.3 Hz, 1H, Haromat.), 7.67 (s, 1H, HC5\u2032), 5.49 (s, 2H, CH2), 4.40 (t, J = 7.0 Hz, 2H, PCH2CH2), 4. diethyl 4-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylbutylphosphonate: Yield 88% (after crystallization from an ethyl acetate\u2013hexane mixture). 151 MHz, CDCl3): = 163.25, 163.22, 143.41, 133.43, 131.43, 131.09, 130.65, 130.50, 129.05, 128.06, 123.17, 122.96, 122.08, 61.54 (d, J = 7.6 Hz, 2 POC), 49.64, 35.33, 30.74 (d, J = 13.6 Hz, PCCC), 24.95 8.44 (d, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 8.26 (d, J = 7.9 Hz, 1H, Haromat.), 7.94 (d, J = 7.9 Hz, 1H, Haromat.), 7.88 (s, 1H, HC5\u2032), 7.75 (dd, J = 8.3 Hz, J = 7.3 Hz, 1H, Haromat.), 5.41 (s, diethyl 3-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-yl-2-hydroxypropylphosphonate (15f): Yield 85%. 5H, PCCH, 2 POCH2CH3), 2.10\u20131.60 (m, 2H, PCH2), 1.33 and 1.29 (t, J = 7.0 Hz, 3H, POCH2CH3), 13C-NMR (151 MHz, CDCl3): = 163.30, 163.28, 143.33, 133.47, 131.47, 131.12, 130.64, 130.50, 130.50, 128.07, 128.0 1H-NMR (151 MHz, CDCl3): = 163.25, 163.23, 143.32, 131.43, 130.67, 130.45, 129.08, 128.08, 124.21, 123.00, 122.13, 71.32 (d, J = 9.1 Hz, PCOC), 65.16 (d, J = 166.1 Hz, PC), 62.47 (d, J = 6.3 Hz, POC), 50. diethyl 2-(2-4-[(6-Bromo-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy)ethylphosphonate (15h): Yield 86% (after crystallization from an ethyl acetate\u2013hexane mixture). 2OCH2CH2), 4.18\u20133.95 (m, 4H, 2 POCH2CH3), 3.79 (t, J = 5.3 Hz, 2H, PCCOCH2CH2), 3.56 (dt, J = 12.0 Hz, J = 7.5 Hz, 2H, PCH2CH2O), 2.03 (dt, J = 18.4 Hz, J = 7.5 Hz, 2H, PCH2CH2O), 1.25 (t, J chloroform\u2013methanol mixtures (100:1 or 50:1, v/v); a white solid; m.p. 173\u2013174 \u00b0C; IR (KBr): = 3240, 3148, 3071, 2987, 2932, 1703, 1665, 1234, 1025, 752 cm1; 1H-NMR (200 MHz, CDCl3): = 8.52 (dd, J = 7.3 Hz, J = 0.8 d, J = 6.6 Hz, POC), 52.57, 35.25, 35.00 (d, J = 155.4 Hz, PC), 16.30 (d, J = 5.4 Hz, POCC); 31P-NMR (81 MHz, CDCl3): 22.29 ppm. 2H, CH2), 4.66 (d, J = 13.1 Hz, 2H, PCH2), 4.13\u20133.98 (m, 4H, 2 POCH2CH3), 1.22 (2 t, J = 7.0 Hz, 6H, 2 POCH2CH3), 13C-NMR (151 MHz, CDCl3): = 162.70, 162.17, 146.36, 143.43, 135.78, 134.68, 130.23, dd, J = 2.2 Hz, 1H, Haromat.), 9.08 (d, J = 2.2 Hz, 1H, Haromat.), 8.38 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 7.89 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 7.68 (s, 1H, HC5\u2032), 5.46 (s, diethyl 3-4-[(5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylpropylphosphonate (16c): Yield 80% (after crystallization from ethyl acetate) 162.76, 162.25, 146.37, 143.06, 135.77, 134.74, 131.07, 130.26, 129.11, 129.11, 124.56, 124.43, 123.39, 123.08, 61.79 (d, J = 6.0 Hz, POC), 50.00 (d, J = 15.1 Hz, PCCC), 35.50, 23.64 (d, J = 4.4 Hz, PCC Hz, J = 1.1 Hz, 1H, Haromat.), 8.42 (dd, J = 8.3 Hz, J = 1.1 Hz, 1H, Haromat.), 7.94 (dd, J = 8.3 Hz, J = 7.4 Hz, 1H, Haromat.), 7.67 (s, 1H, HC5\u2032), 5.52 (s, 2H, CH2), 4.30 (t, J = 7.1 Hz, 2H, [5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-yl-1-hydroxyethylphosphonate (16e) Yield 83% (after crystallization from an ethyl acetate\u2013hexane mixture) 13C-NMR (151 MHz, CDCl3): = 162.74, 162.21, 146.38, 142.78, 135.73, 134.70, 131.04, 130.23, 129.12, 129.08, 124.98, 124.55, 124.41, 123.08, 67.15 (d, J = 6.6 Hz, POC), 51.55 (d, J = 6.0 Hz, POCC), 16.40 (d, 9.13 (d, J = 2.2 Hz, 1H, Haromat.), 8.79 (dd, J = 7.4 Hz, J = 1.2 Hz, 1H, Haromat.), 8.94 (dd, J = 8.2 Hz, J = 1.2 Hz, 1H, Haromat.), 7.86 (s, 1H, HC5\u2032), 5.53 (s, 2H, CH2), 4.56\u20134.31 (m, 3H, PCCC diethyl 2-4-[(5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy-methylphosphonate (16g): Yield 82% (after crystallization from an ethyl acetate\u2013hexane mixture). d, J = 8.2 Hz, 2H, PCH2O), 1.31 (t, J = 7.1 Hz, 6H, 2 POCH2CH3); 13C-NMR (151 MHz, CDCl3): = 162.72, 162.21, 146.36, 142.92, 135.72, 134.67, 131.04, 130.26, 129.10, 129.07, 124.60, 124.37, 124.31, 9.30 (d, J = 2.2 Hz, 1H, Haromat.), 9.78 (dd, J = 7.2 Hz, 1H, Haromat.), 8.42 (dd, J = 8.3 Hz, J = 1.2 Hz, 1H, Haromat.), 7.93 (dd, J = 8.3 Hz, J = 1.2 Hz, 1H, Haromat.), 7.82 (s, 1H, HC5\u2032), 5.52 ( diethyl 2-4-[(5-Nitro-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylacetamido-methylphosphonate (16i): Yield 91%. 11.8 Hz, J = 6.0 Hz, 2H, PCH2NH. 13C-NMR (151 MHz, DMSO-d6): = 165.93 (d, J = 5.2 Hz, C=O), 162.97, 162.51, 146.36, 142.85, 137.00, 134.60, 131.39, 130.37, 130.04, 129.76, 125.41, 124.35, 123 d, J = 8.2 Hz, 1H, Haromat.), 8.07 (d, J = 8.2 Hz, 1H, Haromat.), 8.95 (d, J = 2.2 Hz, 1H, Haromat.), 7.64 (d, J = 2.2 Hz, 1H, Haromat.), 6.01 (s, 2H, NH2), 5.30 (s, 2H, CH2), 5.01 (d, J = 12.9 Hz, oxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethylphosphonate (17b) Yield 75% (after column chromatography with chloroform\u2013methanol mixtures) .92, 123.70, 123.02, 122.26, 122.19, 122.02, 113.90, 62.12 (d, J = 6.4 Hz, POC), 44.49 (PCC), 35.15, 27.23 (d, J = 141.4 Hz, PC), 16.32 (d, J = 5.7 Hz, PC), 31P-NMR (81 MHz, CDCl3): = 26.33 ppm 7.56 (dd, J = 8.2 Hz, J = 7.3 Hz, 1H, Haromat.), 7.23 (d, J = 2.3 Hz, 1H, Haromat.), 5.49 (s, 2H, CH2), 4.42 (t, J = 6.9 Hz, 2H, PCH2CH2CH2), 4.33 (s, 2H, NH2), 4.11\u20134.04 (m, 4H, 2 POCH2CH3), 2. [de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylbutylphosphonate (17d): Yield 70% (after column chromatography with chloroform\u2013methanol mixtures (100:1 and 50:1, v/v) C-NMR (151 MHz, DMSO-d6): = 163.99, 163.81, 148.39, 143.61, 134.08, 132.15, 127.42, 126.04, 123.55, 122.97, 122.34, 122.17, 121.14, 112.38, 61.26 (d, J = 6.0 Hz, 2 POC), 49.16, 35.67, 30.64 (d 8.05 (d, J = 8.2 Hz, 1H, Haromat.), 8.05 (s, 1H, HC5\u2032), 7.99 (d, J = 2.3 Hz, 1H, Haromat.), 7.30 (d, J = 2.3 Hz, 1H, Haromat.), 6.28 (s, 2H, NH2), 5.28 (s, 2H, CH2), 4.52 (dt, J = 14.2 Hz, J = 3.7 diethyl 3-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-yl-2-hydroxypropylphosphonate (17f): Yield 75%. dd, J = 13.8 Hz, J = 7.7 Hz, 1H, PCCCHaHb), 4.15\u20134.09 (m, 1H, PCCH), 4.02\u20133.93 (m, 4H, 2 POCH2CH3), 1.97 (ddd, J = 18.0 Hz, J = 15.4 Hz, J = 5.3 Hz, 1H, PCHaHb), 1.21 (t, J = 7.0 Hz, 3H, PO diethyl 2-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylethoxy-methylphosphonate (17g) Yield 77% (after column chromatography with chloroform\u2013methanol mixtures (100:1 or 50:1, v/v) MR (151 MHz, DMSO-d6): = 164.04, 163.80, 148.40, 143.56, 134.09, 132.17, 127.44, 126.06, 123.97, 122.97, 122.35, 122.17, 121.15, 112.40, 71.00 (d, J = 11.6 Hz, PCOC), 64.31 (d, J = 6.3 Hz, POC), 49. 8.06 (d, J = 2.2 Hz, 1H, Haromat.), 7.82 (d, J = 8.2 Hz, 1H, Haromat.), 7.78 (s, 1H, HC5\u2032), 7.54 (d, J = 2.2 Hz, J = 7.2 Hz,1H, Haromat.), 6.64 (d, J = 5.6 Hz, POCC); 31P-NMR (243 MHz, CDCl3): = 27. diethyl 2-4-[(5-Amino-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)methyl]-1H-1,2,3-triazol-1-ylacetamido-methylphosphonate (17i): Yield 96%. t, J = 6.9 Hz, 6H, 2 POCH2CH3); 13C-NMR (151 MHz, DMSO-d6): = 165.97 (d, J = 4.5 Hz, C=O), 164.00, 163.82, 148.39, 143.40, 134.08, 132.19, 127.45, 126.08, 125.18, 122.93, 122.35, 121.12, 112.4 antiviral activity was expressed as the EC50 or compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50%. the cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) diethyl 4-[(5-substituted-1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl)-methyl]-1H-1,2,3-triazol-1-ylalkylphosphonates was synthesized in good to excellent yields via Cu(I)-catalyzed cycloaddition of N-propargyl naphthalimides 7/8 and 11/12 compounds with longer linkers showed higher cytostatic potency than shorter fragments. compounds with longer linkers showed higher cytostatic potency."}